Research and Markets: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Insights - Provides a Radiation Toxicity Landscape Across the Globe

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/c77tbc/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Insights" report to their offering.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Scope

  • The report provides a Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Landscape across the globe
  • The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
  • Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and also provide company profiling

Key Topics Covered:

  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Therapeutics
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics under Development by Companies
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Late Stage Products (Filed and Phase III)
  • Comparative Analysis
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Mid Clinical Stage Products (Phase II)
  • Comparative Analysis
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Early Clinical Stage Products (Phase I and IND Filed)
  • Comparative Analysis
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Drug Candidate Profiles
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Products
  • Companies Involved in Therapeutics Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

For more information visit http://www.researchandmarkets.com/research/c77tbc/radiation

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals